Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports
July 29, 2020 07:30 ET
|
Fortress Biotech, Inc.
Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of...
Fortress Biotech Added to Russell 3000® Index
June 29, 2020 08:30 ET
|
Fortress Biotech, Inc.
Avenue Therapeutics (ATXI), a Fortress partner company, also added NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical...
Fortress Biotech to Present at the Raymond James Human Health Innovation Conference
June 15, 2020 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing...
Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports
June 11, 2020 08:00 ET
|
Fortress Biotech, Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing...
Fortress Biotech to Host Virtual Annual Meeting of Stockholders
June 02, 2020 08:30 ET
|
Fortress Biotech, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that it will host the Company’s 2020 Annual...
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
May 26, 2020 21:30 ET
|
Fortress Biotech, Inc.
NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced...
Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights
May 11, 2020 16:30 ET
|
Fortress Biotech, Inc.
First quarter 2020 product revenue increased 95% year-over-year to $11.9 million NDA for IV tramadol accepted for review by FDA; assigned PDUFA date of October 10, 2020 Agreement executed with...
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers
May 08, 2020 07:30 ET
|
Fortress Biotech, Inc.
Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is KRAS-driven cancers,...
Fortress Biotech Announces Up to $5 Million Series A Cumulative Redeemable Perpetual Preferred Stock Repurchase Program
March 23, 2020 09:20 ET
|
Fortress Biotech, Inc.
NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on acquiring, developing and...
Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights
March 16, 2020 16:45 ET
|
Fortress Biotech, Inc.
Revenue from marketed dermatology products increased 85% for fourth quarter 2019 and 49% for full-year 2019 compared to 2018 NDA for IV tramadol accepted for review by FDA; PDUFA date is set for...